National Oncology Conference BJCN-MORÉ 2024
Agenda
Management of cholangiocarcinoma
AI Revolution in Oncology:
technological trajectories, marketing and ethics
Scientific agenda
17 October
18 October
19 October
20 October
17 October
Registration
Official opening
Annual Award BJCN-MORÉ – for contribution to Bulgarian clinical
oncology
Industry Satellite Symposium Novartis
Moderator: Assoc. Prof. J. Arabadjiev, MD, PhD
14:20 – 14:40 New moments in prostate and breast cancer treatment from the latest international scientific events
Assoc. Prof. J. Arabadjiev, MD, PhD
14:40 – 15:00 Successes in prostate cancer treatment – can we do more
R. Mangaldjiev, MD
15:00 – 15:20 Possibilities of modern radioligand therapy
Assoc. Prof. V. Hadjiiska, MD, PhD
15:20 – 15:40 Adjuvant breast cancer treatment – what we have achieved and how it will be in the future
Assoc. Prof. A. Konsoulova, MD, PhD
14:20 – 14:40 New moments in prostate and breast cancer treatment from the latest international scientific events
Assoc. Prof. J. Arabadjiev, MD, PhD
14:40 – 15:00 Successes in prostate cancer treatment – can we do more
R. Mangaldjiev, MD
15:00 – 15:20 Possibilities of modern radioligand therapy
Assoc. Prof. V. Hadjiiska, MD, PhD
15:20 – 15:40 Adjuvant breast cancer treatment – what we have achieved and how it will be in the future
Assoc. Prof. A. Konsoulova, MD, PhD
Industry Satellite Symposium Swixx BioPharma
Cholangiocarcinoma – refining and personalizing therapy
Moderator: М. Кoleva, MD
15:45 – 16:05 Cholangiocarcinoma – current paradigms and principles
R. Mangaldjiev, MD
16:05 – 16:25 The role of FGFR
Prof. S. Popovska, MD, PhD
16:25 – 16:45 Study FIGHT-202
Tc. Yordanov, MD
15:45 – 16:05 Cholangiocarcinoma – current paradigms and principles
R. Mangaldjiev, MD
16:05 – 16:25 The role of FGFR
Prof. S. Popovska, MD, PhD
16:25 – 16:45 Study FIGHT-202
Tc. Yordanov, MD
Coffee break
Industry Satellite Symposium Janssen (J&J)
Current Therapeutic Opportunities by J&J Innovative Medicine
Moderator: Assoc. Prof. D. Kalev, MD, PhD
17:00 – 17:05 Opening remarks
17:05 – 17:25 Erleada® and triplet therapy in the treatment of metastatic hormone- sensitive prostate cancer: How to evaluate treatment options
R. Mangaljiev, MD
17:25 – 17:45 Rybrevant®: The first immunotherapy approved for the treatment of patients with non-small cell lung cancer harboring EGFR Exon 20 insertion mutations
K. Koynov, MD
17:45 – 18:00 Discussion and closing remarks
Moderator: Assoc. Prof. D. Kalev, MD, PhD
17:00 – 17:05 Opening remarks
17:05 – 17:25 Erleada® and triplet therapy in the treatment of metastatic hormone- sensitive prostate cancer: How to evaluate treatment options
R. Mangaljiev, MD
17:25 – 17:45 Rybrevant®: The first immunotherapy approved for the treatment of patients with non-small cell lung cancer harboring EGFR Exon 20 insertion mutations
K. Koynov, MD
17:45 – 18:00 Discussion and closing remarks
Moderator: Assoc. Prof. D. Kalev, MD, PhD
Industry Satellite Symposium Varia
Moderator: Assoc. Prof. J. Arabadjiev, MD, PhD
18:05 – 18:25 Corporate presentation Eli Lilly
Treatment of patients with ER+, HER2– early breast cancer – High-risk therapy
Assoc. Prof. A. Konsoulova, MD, PhD
18:25 – 18:45 Corporate presentation Astellas
Padcev™ (enfortumab vedotin) – A journey beyond the horizon in the treatment of advanced urothelial carcinoma
V. Kanarev, MD
18:45 – 19:05 1st Corporate presentation Roche
Subcutaneous administration of Tecentriq as an opportunity to optimize the route of administration of immunotherapy
Assoc. Prof. A. Konsoulova, MD, PhD
19:05 – 19:25 2nd Corporate presentation Roche
Adjuvant Alecensa: a new therapeutic strategy in early ALK+ non-small cell lung carcinoma
Assoc. Prof. J. Arabadjiev, MD, PhD
19:25 – 19:45 Corporate presentation Amgen
Multi omics biomarker analyzes in metastatic colorectal carcinoma – practical significance for determining therapeutic behavior
L. Simeonova, MD
18:05 – 18:25 Corporate presentation Eli Lilly
Treatment of patients with ER+, HER2– early breast cancer – High-risk therapy
Assoc. Prof. A. Konsoulova, MD, PhD
18:25 – 18:45 Corporate presentation Astellas
Padcev™ (enfortumab vedotin) – A journey beyond the horizon in the treatment of advanced urothelial carcinoma
V. Kanarev, MD
18:45 – 19:05 1st Corporate presentation Roche
Subcutaneous administration of Tecentriq as an opportunity to optimize the route of administration of immunotherapy
Assoc. Prof. A. Konsoulova, MD, PhD
19:05 – 19:25 2nd Corporate presentation Roche
Adjuvant Alecensa: a new therapeutic strategy in early ALK+ non-small cell lung carcinoma
Assoc. Prof. J. Arabadjiev, MD, PhD
19:25 – 19:45 Corporate presentation Amgen
Multi omics biomarker analyzes in metastatic colorectal carcinoma – practical significance for determining therapeutic behavior
L. Simeonova, MD
Welcome dinner
18 October
Registration
FIRST PLENARY SESSION
Diagnostic and Pre-therapeutic Issues in Cholangiocarcinoma
Chairwoman: Prof. S. Popovska, MD, PhD
08:00 – 08:15 Elevation of serum biomarker CA19-9 in cholangiocarcinoma – benefits and dilemmas
V. Koleva, MD
08:20 – 08:35 Genomic landscape of cholangiocarcinoma types
L. Balabanski, Prof. D. Toncheva, MD, PhD
08:40 – 08:55 Molecular pathologic and clinical parallels between small and large duct intrahepatic cholangiocarcinoma
Assoc. Prof. I. Ivanov, MD, Prof. S. Popovska, MD, PhD
09:00 – 09:15 Histology of cholangiocarcinoma – beyond the ordinary
Assoc. Prof. V. Ivanova, MD, PhD
09:20 – 09:35 Classificatory and prognostic role of imaging features in intrahepatic cholangiocarcinoma
Assoc. Prof. M. Penkov, MD, PhD, D. Videva, MD
09:40 – 09:55 Imaging modalities for the assessment of resectability in perihilar cholangiocarcinoma
Assoc. Prof. P. Getzov, MD, PhD
10:00 – 10:15 PET/CT assessment of global burden of disease in cholangiocarcinoma – prognosis and prediction
Prof. E. Piperkova, MD, PhD, Assoc. Prof. L. Chavdarova, MD, PhD, Prof. I. Kostadinova, MD, PhD
10:20 – 10:35 PET/CT-based radiomics in cholangiocarcinoma – expected clinical benefits
Assoc. Prof. V. Hadjiiska, MD, PhD
08:00 – 08:15 Elevation of serum biomarker CA19-9 in cholangiocarcinoma – benefits and dilemmas
V. Koleva, MD
08:20 – 08:35 Genomic landscape of cholangiocarcinoma types
L. Balabanski, Prof. D. Toncheva, MD, PhD
08:40 – 08:55 Molecular pathologic and clinical parallels between small and large duct intrahepatic cholangiocarcinoma
Assoc. Prof. I. Ivanov, MD, Prof. S. Popovska, MD, PhD
09:00 – 09:15 Histology of cholangiocarcinoma – beyond the ordinary
Assoc. Prof. V. Ivanova, MD, PhD
09:20 – 09:35 Classificatory and prognostic role of imaging features in intrahepatic cholangiocarcinoma
Assoc. Prof. M. Penkov, MD, PhD, D. Videva, MD
09:40 – 09:55 Imaging modalities for the assessment of resectability in perihilar cholangiocarcinoma
Assoc. Prof. P. Getzov, MD, PhD
10:00 – 10:15 PET/CT assessment of global burden of disease in cholangiocarcinoma – prognosis and prediction
Prof. E. Piperkova, MD, PhD, Assoc. Prof. L. Chavdarova, MD, PhD, Prof. I. Kostadinova, MD, PhD
10:20 – 10:35 PET/CT-based radiomics in cholangiocarcinoma – expected clinical benefits
Assoc. Prof. V. Hadjiiska, MD, PhD
Coffee break
SECOND PLENARY SESSION
Invasive and Surgical Strategies for Cholangiocarcinoma (1)
Chairman: Prof. N. Vladov, MD, PhD
11:00 – 11:15 Pre-operative classifications of perihilar cholangiocarcinoma
Assoc. Prof. V. Mihaylov, MD, PhD, C. Trichkov, MD
11:20 – 11:35 Anomalous pancreaticobiliary confluence – a risk factor and indication for cholangiocarcinoma risk-reduction surgery
Prof. A. Julianov, MD, PhD, A. Saroglu, MD
11:40 – 11:55 Strategies for the liver remnant future optimization
Assoc. Prof. C. Lukanova, MD, PhD, R. Kostadinov, MD
12:00 – 12:15 Biliary drainage – in preoperative and/or advanced planning
Assoc. Prof. A. Katzarov, MD, PhD
12:20 – 12:35 Peritoneal cytology in cholangiocarcinoma – prognostic value
Assoc. Prof. S. Bachurska, MD, PhD
12:40 – 12:55 Vascular resections in cholangiocarcinoma
Prof. D. Kostov, MD, PhD
11:00 – 11:15 Pre-operative classifications of perihilar cholangiocarcinoma
Assoc. Prof. V. Mihaylov, MD, PhD, C. Trichkov, MD
11:20 – 11:35 Anomalous pancreaticobiliary confluence – a risk factor and indication for cholangiocarcinoma risk-reduction surgery
Prof. A. Julianov, MD, PhD, A. Saroglu, MD
11:40 – 11:55 Strategies for the liver remnant future optimization
Assoc. Prof. C. Lukanova, MD, PhD, R. Kostadinov, MD
12:00 – 12:15 Biliary drainage – in preoperative and/or advanced planning
Assoc. Prof. A. Katzarov, MD, PhD
12:20 – 12:35 Peritoneal cytology in cholangiocarcinoma – prognostic value
Assoc. Prof. S. Bachurska, MD, PhD
12:40 – 12:55 Vascular resections in cholangiocarcinoma
Prof. D. Kostov, MD, PhD
Lunch
THIRD PLENARY SESSION
Invasive and Surgical Strategies for Cholangiocarcinoma (2)
Chairmen: Prof. N. Vladov, MD, PhD
14:00 – 14:15 Peculiarities of surgical treatment in gallbladder cancer
Assoc. Prof. N. Belev, MD, PhD
14:20 – 14:35 When is reexploration necessary after routine cholecystectomy with incidentally discovered gallbladder cancer
Prof. K. Draganov, MD, PhD, A. Petreska, MD
14:40 – 14:55 Local strategies for perihilar and distal cholangiocarcinoma – evidence and recommendations
Assoc. Prof. P. Karagyozov, MD, PhD
15:00 – 15:15 Liver transplantation – how to select cholangiocarcinoma patients
Prof. I. Takorov, MD, PhD
14:00 – 14:15 Peculiarities of surgical treatment in gallbladder cancer
Assoc. Prof. N. Belev, MD, PhD
14:20 – 14:35 When is reexploration necessary after routine cholecystectomy with incidentally discovered gallbladder cancer
Prof. K. Draganov, MD, PhD, A. Petreska, MD
14:40 – 14:55 Local strategies for perihilar and distal cholangiocarcinoma – evidence and recommendations
Assoc. Prof. P. Karagyozov, MD, PhD
15:00 – 15:15 Liver transplantation – how to select cholangiocarcinoma patients
Prof. I. Takorov, MD, PhD
Coffee break
FOURTH PLENARY SESSION
Systemic and radiotherapy approaches in cholangiocarcinoma
Chairwoman: Assoc. Prof. A. Konsoulova, MD, PhD
15:40 – 15:55 Arguments and reservations for neoadjuvant systemic therapy in resectable cholangiocarcinoma
M. Taushanova, MD, K. Koynov, MD
16:00 – 16:15 Definitive radiotherapy strategies for unresectable cholangiocarcinoma – Why, When, How
Prof. T. Hadzhieva, MD, PhD, M. Koleva, MD
16:20 – 16:35 Adjuvant systemic therapy for resected cholangiocarcinoma – is capecitabine the standard
T. Zlatanova, MD
16:40 – 16:55 Postoperative radiotherapy for gallbladder cancer and distal cholangiocarcinoma
K. Jordanov, MD, K. Nedev, MD
17:00 – 17:15 First- and second-line chemotherapy in cholangiocarcinoma – is the tradition relevant?
Assoc. Prof. A. Konsoulova, MD, PhD
17:20 – 17:35 Immunotherapy in advanced cholangiocarcinoma – present or future
R. Mangaldjiev, MD
17:40 – 17:55 Dietary issues during and after cholangiocarcinoma treatment
Assoc. Prof. N. Jordanov, MD, PhD
18:00 – 18:15 The role of cannabidiol in cholangiocarcinoma – from empiricism to evidence
M. Koleva, MD
15:40 – 15:55 Arguments and reservations for neoadjuvant systemic therapy in resectable cholangiocarcinoma
M. Taushanova, MD, K. Koynov, MD
16:00 – 16:15 Definitive radiotherapy strategies for unresectable cholangiocarcinoma – Why, When, How
Prof. T. Hadzhieva, MD, PhD, M. Koleva, MD
16:20 – 16:35 Adjuvant systemic therapy for resected cholangiocarcinoma – is capecitabine the standard
T. Zlatanova, MD
16:40 – 16:55 Postoperative radiotherapy for gallbladder cancer and distal cholangiocarcinoma
K. Jordanov, MD, K. Nedev, MD
17:00 – 17:15 First- and second-line chemotherapy in cholangiocarcinoma – is the tradition relevant?
Assoc. Prof. A. Konsoulova, MD, PhD
17:20 – 17:35 Immunotherapy in advanced cholangiocarcinoma – present or future
R. Mangaldjiev, MD
17:40 – 17:55 Dietary issues during and after cholangiocarcinoma treatment
Assoc. Prof. N. Jordanov, MD, PhD
18:00 – 18:15 The role of cannabidiol in cholangiocarcinoma – from empiricism to evidence
M. Koleva, MD
Industry Satellite Symposium Pfizer
More hope for patients with ALK+ non-small cell lung cancer and HR+/HER2– metastatic breast cancer
Мoderator: Assoc. Prof. A. Konsoulova, MD, PhD
18:20 – 18:40 Exceptional over 5-year PFS in first-line treatment of ALK+ NSCLC
К. Коynov, MD
18:40 – 19:00 A personalized approach in patients with HR+/HER2– metastatic breast cancer based on real-world data
P. Balikova, MD
19:00 – 19:20 Discussion
Мoderator: Assoc. Prof. A. Konsoulova, MD, PhD
18:20 – 18:40 Exceptional over 5-year PFS in first-line treatment of ALK+ NSCLC
К. Коynov, MD
18:40 – 19:00 A personalized approach in patients with HR+/HER2– metastatic breast cancer based on real-world data
P. Balikova, MD
19:00 – 19:20 Discussion
Мoderator: Assoc. Prof. A. Konsoulova, MD, PhD
FIRST JOINT SESSION BY BULGARIAN JOINT CANCER NETWORK
Integrative Oncology and Dietetics
Chairmen: P. Zagorchev, MD
19:25 – 19:45 Homeopathic supportive care in oncology: Focus on surgical monitoring and diarrhea
J-C. Karp, MD (Troyes University Hospital, France)
19:50 – 20:15 Nutrition specificity in cholangiocarcinoma
Prof. D. Naydenova, MD, PhD
19:25 – 19:45 Homeopathic supportive care in oncology: Focus on surgical monitoring and diarrhea
J-C. Karp, MD (Troyes University Hospital, France)
19:50 – 20:15 Nutrition specificity in cholangiocarcinoma
Prof. D. Naydenova, MD, PhD
Dinner
19 October
Registration
SECOND JOINT SESSION BY BULGARIAN JOINT CANCER NETWORK
Deep-Health Tech and Artificial Intelligence (AI) in Cancer Care – Convergence
Moderators: M. Ganova (DHI Bulgaria), I. Lekushev (BGO Software)
Panel discussion with: H. Ivanov (Shemha Health), P. Mihailov (MY Synergy), G. Kostadinov (Kelvin Health), V. Tafrajiisky (Software Company)
Panel discussion with: H. Ivanov (Shemha Health), P. Mihailov (MY Synergy), G. Kostadinov (Kelvin Health), V. Tafrajiisky (Software Company)
Industry Satellite Symposium MSD
Moderator: Assoc. Prof. D. Kalev, MD, PhD
09:20 – 09:25 Opening remarks
09:25 – 09:45 Pembrolizumab treatment options for esophageal carcinoma
I. Nikolov, MD
09:45 – 10:05 The place of Pembrolizumab in the management of HER2-positive gastric or gastroesophageal junction carcinoma
K. Koynov, MD
10:05 – 10:20 Discussion and closing remarks
Moderator: Assoc. Prof. D. Kalev, MD, PhD
09:20 – 09:25 Opening remarks
09:25 – 09:45 Pembrolizumab treatment options for esophageal carcinoma
I. Nikolov, MD
09:45 – 10:05 The place of Pembrolizumab in the management of HER2-positive gastric or gastroesophageal junction carcinoma
K. Koynov, MD
10:05 – 10:20 Discussion and closing remarks
Moderator: Assoc. Prof. D. Kalev, MD, PhD
Coffee break
Industry Satellite Symposium Pierre Fabre
Moderators: G. Shalamanova, MD, and Assoc. Prof. I. Gavrilova, MD
The role of targeted therapy in melanoma treatment in 2024
Prof. H. Gogas, MD
The role of targeted therapy in melanoma treatment in 2024
Prof. H. Gogas, MD
THIRD JOINT SESSION BY BULGARIAN JOINT CANCER NETWORK
Artificial Intelligence (AI) in Cancer Care – Ethic, Clinical and Regulatory Norms in Bulgaria
Moderator: Assoc. Prof. B. Borissov, MD, PhD
Panel discussion with: Prof. M. Lazarova (Legal Expert), P. Murgova (Law office Murgova and partners),D. Denev (ARPharM), A. Simidchiev, MD (Chairman of the Parliamentary Healthcare Commission, Member of the Bulgarian Parliament), R. Mangaldjiev, MD (Medical Oncologist), Assoc. Prof. J. Arabadjiev, MD, PhD (Board member EU Mission on Cancer; President of Bulgarian Scientific Society of Immuno-oncology), S. Hasardjiev, MD (President of National Patient Organization, Bulgaria)
Panel discussion with: Prof. M. Lazarova (Legal Expert), P. Murgova (Law office Murgova and partners),D. Denev (ARPharM), A. Simidchiev, MD (Chairman of the Parliamentary Healthcare Commission, Member of the Bulgarian Parliament), R. Mangaldjiev, MD (Medical Oncologist), Assoc. Prof. J. Arabadjiev, MD, PhD (Board member EU Mission on Cancer; President of Bulgarian Scientific Society of Immuno-oncology), S. Hasardjiev, MD (President of National Patient Organization, Bulgaria)
Lunch
FOURTH JOINT SESSION BY BULGARIAN JOINT CANCER NETWORK
Artificial Intelligence (AI) in Cancer Care: Sustainable Systems Solutions – Innovative Approaches for Efficiency
Moderator: G. Kapetanakis (President of the Hellenic Cancer Federation – ELLOK)
Panel discussion with: E. Pisani (CEO, All.Can International), D. Georgiev, MD (Bulgarian Association for Personalized Medicine), Prof. B. Vassileva, PhD (Vice–Rector of University of Economics – Varna), I. Cattaneo (EFPIA Oncology Working Group), M. Stoycheva (ex-Minister of Ministry of Innovations and Growth, Bulgaria), A. Simidchiev, MD (Chairman of the Parliamentary Healthcare Commission, Member of the Bulgarian Parliament)
Panel discussion with: E. Pisani (CEO, All.Can International), D. Georgiev, MD (Bulgarian Association for Personalized Medicine), Prof. B. Vassileva, PhD (Vice–Rector of University of Economics – Varna), I. Cattaneo (EFPIA Oncology Working Group), M. Stoycheva (ex-Minister of Ministry of Innovations and Growth, Bulgaria), A. Simidchiev, MD (Chairman of the Parliamentary Healthcare Commission, Member of the Bulgarian Parliament)
FIFTH JOINT SESSION BY BULGARIAN JOINT CANCER NETWORK
Artificial Intelligence (AI) in Cancer Care: Sustainable Systems Solutions – Policies, Sustainable and Impactful Practices
Moderator: M. Geanta, MD (President of the Center for Innovation in Medicine, Romania)
Panel discussion with: R. Price (European Cancer Organization), P. Gunther (Board EU Cancer Mission), Ch. Chomienne (Vice Chair of the EU Cancer Mission), A. Kovatchev, PhD (Member of European Parliament)
Panel discussion with: R. Price (European Cancer Organization), P. Gunther (Board EU Cancer Mission), Ch. Chomienne (Vice Chair of the EU Cancer Mission), A. Kovatchev, PhD (Member of European Parliament)
Coffee break
Industry Satellite Symposium AstraZeneca
A significant step forward in the treatment of genitourinary and gastrointestinal carcinoma
17:00 – 17:25 Genitourinary Carcinoma Module
Establish an approach in the treatment of mCRPC
K. Koynov, MD
17:25 – 18:00 Gastrointestinal Carcinoma Module
Мoderator: Assoc. Prof. J. Arabadjiev, MD, PhD
17:25 – 17:40 Long-term benefit in the treatment of unresectable or metastatic bile duct carcinoma
Assoc. Prof. J. Arabadjiev, MD, PhD
17:40 – 18:00 A significant step forward in the treatment of hepatocellular carcinoma with IO-IO
M. Koleva, MD
Establish an approach in the treatment of mCRPC
K. Koynov, MD
17:25 – 18:00 Gastrointestinal Carcinoma Module
Мoderator: Assoc. Prof. J. Arabadjiev, MD, PhD
17:25 – 17:40 Long-term benefit in the treatment of unresectable or metastatic bile duct carcinoma
Assoc. Prof. J. Arabadjiev, MD, PhD
17:40 – 18:00 A significant step forward in the treatment of hepatocellular carcinoma with IO-IO
M. Koleva, MD
Industry Satellite Symposium BMS
Immuno-oncology in gastroesophageal tumors: pathways to better treatment
Мoderator: Assoc. Prof Assya Konsoulova, MD
18:05 – 18:15 Histological features of gastroesophageal tumors
Assoc. Prof. S. Bachurska, MD, PhD
18:15 – 18:25 CheckMate 649: Advanced carcinoma of the stomach, gastroesophageal junction, and esophagus
V. Marinova, MD
18:25 – 18:35 From trials to practice – sharing clinical experience
I. Koleva, MD
18:05 – 18:15 Histological features of gastroesophageal tumors
Assoc. Prof. S. Bachurska, MD, PhD
18:15 – 18:25 CheckMate 649: Advanced carcinoma of the stomach, gastroesophageal junction, and esophagus
V. Marinova, MD
18:25 – 18:35 From trials to practice – sharing clinical experience
I. Koleva, MD
SIXTH JOINT SESSION BY BULGARIAN JOINT CANCER NETWORK
From Establishing of Cancer Mission Hubs: Networks and Synergies (ECHoS) toward the Bulgarian National Cancer Mission Hub (NCMH)
Moderator: Assoc. Prof. J. Arabadjiev, MD, PhD (Board member EU Mission on Cancer)
Panel discussion with: A. Isidro (ECHoS Coordinator), G. Kapetanakis (President of the Hellenic Cancer Federation – ELLOK), M. Geanta (President of the Center for Innovation in Medicine, Romania), Assoc. Prof. A. Konsoulova, MD, PhD (Board Member of BJCN), I. Petrov (Public Affairs & Projects Lead at BJCN), I. Cattaneo (ECHoS Advisory Board Member), Prof. S. Popovska (Medical University – Pleven)
Panel discussion with: A. Isidro (ECHoS Coordinator), G. Kapetanakis (President of the Hellenic Cancer Federation – ELLOK), M. Geanta (President of the Center for Innovation in Medicine, Romania), Assoc. Prof. A. Konsoulova, MD, PhD (Board Member of BJCN), I. Petrov (Public Affairs & Projects Lead at BJCN), I. Cattaneo (ECHoS Advisory Board Member), Prof. S. Popovska (Medical University – Pleven)
Official closing
Dinner
20 October
GENERAL ASSEMBLY OF BULGARIAN JOINT CANCER NETWORK (BJCN)
17 October
18 October
19 October
20 October
17 October
18 October
19 October
20 October
